CU20100144A7 - Composiciones vacunales a base de sticholisina encapsulada en liposomas - Google Patents
Composiciones vacunales a base de sticholisina encapsulada en liposomasInfo
- Publication number
- CU20100144A7 CU20100144A7 CU20100144A CU20100144A CU20100144A7 CU 20100144 A7 CU20100144 A7 CU 20100144A7 CU 20100144 A CU20100144 A CU 20100144A CU 20100144 A CU20100144 A CU 20100144A CU 20100144 A7 CU20100144 A7 CU 20100144A7
- Authority
- CU
- Cuba
- Prior art keywords
- encapsulated
- liposomes
- immune response
- sticholisine
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con el campo de Biotecnología aplicada a la salud humana. En la misma se describe un vehículo vacunal donde se encapsula toxinas provenientes de organismos eucariontes en liposomas de múltiples capas lipídicas obtenidos por el procedimiento de deshidratación-rehidratación cuya composición lipídica es dipalmitoilfosfatidilcolina: colesterol en una relación molar 1:1, destinadas a la administración subcutánea o intramuscular. Estas composiciones no requieren del empleo de otros adyuvantes. Las composiciones descritas posibilitan la modulación de la respuesta inmune CTL específica contra uno o varios antígenos co-encapsulados en liposomas que contienen la toxina. El vehículo vacunal de la presente invención presenta ventajas frente a otros descritos por el arte previo debido a la robustez y funcionalidad de la respuesta inmune que induce así como a sus propiedades inmumoduladoras.
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20100144A CU20100144A7 (es) | 2010-07-06 | 2010-07-06 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
UAA201301383A UA111944C2 (uk) | 2010-07-06 | 2011-05-07 | Вакцинна композиція на основі стихолізину, інкапсульованого в ліпосоми |
ARP110102211A AR081661A1 (es) | 2010-07-06 | 2011-06-24 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
TW100122821A TWI457145B (zh) | 2010-07-06 | 2011-06-29 | 以被包封於微脂粒內之蒂卡琳素(sticholysin)為基礎的疫苗組成物 |
ES11743950.5T ES2576851T3 (es) | 2010-07-06 | 2011-07-05 | Composiciones vacunales a base de sticholisina encapsuladas en llposomas |
US13/808,276 US8697093B2 (en) | 2010-07-06 | 2011-07-05 | Vaccine composition based on sticholysin encapsulated into liposomes |
CA2802443A CA2802443C (en) | 2010-07-06 | 2011-07-05 | Vaccine compositions based on sticholysin encapsulated in liposomes |
EA201291449A EA025333B1 (ru) | 2010-07-06 | 2011-07-05 | Вакцинный носитель для индукции клеточного иммунного ответа |
SG2013000690A SG186931A1 (en) | 2010-07-06 | 2011-07-05 | Vaccine compositions based on sticholysin encapsulated in liposomes |
KR1020137000208A KR101455055B1 (ko) | 2010-07-06 | 2011-07-05 | 리포솜으로 캡슐화된 스티코리신에 따른 백신 조성물 |
AU2011276812A AU2011276812B2 (en) | 2010-07-06 | 2011-07-05 | Vaccine compositions based on sticholysin encapsulated in liposomes |
MYPI2013000019A MY167896A (en) | 2010-07-06 | 2011-07-05 | Vaccine composition based on sticholysin encapsulated into liposomes. |
PCT/CU2011/000004 WO2012003814A1 (es) | 2010-07-06 | 2011-07-05 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
MX2012015173A MX2012015173A (es) | 2010-07-06 | 2011-07-05 | Composiciones vacunales a base de sticholisina encapsulada en liposomas. |
PE2013000004A PE20130390A1 (es) | 2010-07-06 | 2011-07-05 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
BR112012033284-8A BR112012033284B1 (pt) | 2010-07-06 | 2011-07-05 | veículo vacinal para induzir resposta imune celular, e, composição vacinal |
JP2013517001A JP5685646B2 (ja) | 2010-07-06 | 2011-07-05 | リポソーム中にカプセル化されたスチコリシンに基づくワクチン組成物 |
CN201180033067.XA CN102971011B (zh) | 2010-07-06 | 2011-07-05 | 基于包囊在脂质体中的海葵溶细胞素的疫苗组合物 |
EP11743950.5A EP2591802B1 (en) | 2010-07-06 | 2011-07-05 | Vaccine compositions based on sticholysin encapsulated in liposomes |
TNP2012000592A TN2012000592A1 (en) | 2010-07-06 | 2012-12-13 | Vaccine compositions based on sticholysin encapsulated in liposomes |
CO12229159A CO6640312A2 (es) | 2010-07-06 | 2012-12-18 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
CL2012003674A CL2012003674A1 (es) | 2010-07-06 | 2012-12-21 | Vehiculo vacunal para inducir respuesta inmune celular que comprende la encapsulación en vesículas lipídicas de proteínas obtenidas de la anémona stichodactyla helianthus junto con un antígeno; composicion vacunal que comprende el vehiculo vacunal; uso de la composicion para reforzamiento de la respuesta inmune. |
ZA2013/00059A ZA201300059B (en) | 2010-07-06 | 2013-01-03 | Vaccine compositions based on sticholysin encapsulated in liposomes |
HK13104046.1A HK1177138A1 (en) | 2010-07-06 | 2013-04-02 | Vaccine compositions based on sticholysin encapsulated in liposomes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20100144A CU20100144A7 (es) | 2010-07-06 | 2010-07-06 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20100144A7 true CU20100144A7 (es) | 2012-06-21 |
Family
ID=44533576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20100144A CU20100144A7 (es) | 2010-07-06 | 2010-07-06 | Composiciones vacunales a base de sticholisina encapsulada en liposomas |
Country Status (24)
Country | Link |
---|---|
US (1) | US8697093B2 (es) |
EP (1) | EP2591802B1 (es) |
JP (1) | JP5685646B2 (es) |
KR (1) | KR101455055B1 (es) |
CN (1) | CN102971011B (es) |
AR (1) | AR081661A1 (es) |
AU (1) | AU2011276812B2 (es) |
BR (1) | BR112012033284B1 (es) |
CA (1) | CA2802443C (es) |
CL (1) | CL2012003674A1 (es) |
CO (1) | CO6640312A2 (es) |
CU (1) | CU20100144A7 (es) |
EA (1) | EA025333B1 (es) |
ES (1) | ES2576851T3 (es) |
HK (1) | HK1177138A1 (es) |
MX (1) | MX2012015173A (es) |
MY (1) | MY167896A (es) |
PE (1) | PE20130390A1 (es) |
SG (1) | SG186931A1 (es) |
TN (1) | TN2012000592A1 (es) |
TW (1) | TWI457145B (es) |
UA (1) | UA111944C2 (es) |
WO (1) | WO2012003814A1 (es) |
ZA (1) | ZA201300059B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014034669A1 (ja) * | 2012-08-28 | 2014-03-06 | 国立大学法人北海道大学 | 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法 |
KR102069670B1 (ko) * | 2017-03-02 | 2020-01-23 | 단디바이오사이언스 주식회사 | 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
JP7409594B2 (ja) * | 2017-07-10 | 2024-01-09 | イミューノヴァクシーン テクノロジーズ インコーポレイテッド | 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 |
CN113041346A (zh) * | 2019-12-26 | 2021-06-29 | 复旦大学 | 一种细菌毒素疫苗及其在预防细菌感染中的用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06500128A (ja) | 1991-05-08 | 1994-01-06 | シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン | 免疫刺激及び免疫増強性再構成インフルエンザウイロソーム及びそれを含有するワクチン |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
EP1797895A1 (en) | 2005-12-16 | 2007-06-20 | Pevion Biotech Ltd. | An adjuvant system comprising virosomes and liposomes |
KR101332538B1 (ko) | 2006-12-04 | 2013-11-22 | 도꾸리쯔 교세이호징 노우교 · 쇼쿠힝 산교 기쥬쯔 소고 겡뀨 기꼬우 | 바이오미네랄 함유물의 제조방법 및 유기 양액재배법 |
-
2010
- 2010-07-06 CU CU20100144A patent/CU20100144A7/es unknown
-
2011
- 2011-05-07 UA UAA201301383A patent/UA111944C2/uk unknown
- 2011-06-24 AR ARP110102211A patent/AR081661A1/es not_active Application Discontinuation
- 2011-06-29 TW TW100122821A patent/TWI457145B/zh active
- 2011-07-05 MX MX2012015173A patent/MX2012015173A/es active IP Right Grant
- 2011-07-05 US US13/808,276 patent/US8697093B2/en active Active
- 2011-07-05 JP JP2013517001A patent/JP5685646B2/ja active Active
- 2011-07-05 WO PCT/CU2011/000004 patent/WO2012003814A1/es active Application Filing
- 2011-07-05 SG SG2013000690A patent/SG186931A1/en unknown
- 2011-07-05 AU AU2011276812A patent/AU2011276812B2/en active Active
- 2011-07-05 CN CN201180033067.XA patent/CN102971011B/zh active Active
- 2011-07-05 EP EP11743950.5A patent/EP2591802B1/en active Active
- 2011-07-05 ES ES11743950.5T patent/ES2576851T3/es active Active
- 2011-07-05 CA CA2802443A patent/CA2802443C/en active Active
- 2011-07-05 MY MYPI2013000019A patent/MY167896A/en unknown
- 2011-07-05 KR KR1020137000208A patent/KR101455055B1/ko active IP Right Grant
- 2011-07-05 PE PE2013000004A patent/PE20130390A1/es not_active Application Discontinuation
- 2011-07-05 EA EA201291449A patent/EA025333B1/ru not_active IP Right Cessation
- 2011-07-05 BR BR112012033284-8A patent/BR112012033284B1/pt not_active IP Right Cessation
-
2012
- 2012-12-13 TN TNP2012000592A patent/TN2012000592A1/en unknown
- 2012-12-18 CO CO12229159A patent/CO6640312A2/es unknown
- 2012-12-21 CL CL2012003674A patent/CL2012003674A1/es unknown
-
2013
- 2013-01-03 ZA ZA2013/00059A patent/ZA201300059B/en unknown
- 2013-04-02 HK HK13104046.1A patent/HK1177138A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR112012033284B1 (pt) | 2021-05-18 |
MX2012015173A (es) | 2013-02-11 |
UA111944C2 (uk) | 2016-07-11 |
US8697093B2 (en) | 2014-04-15 |
AU2011276812B2 (en) | 2013-12-19 |
EP2591802B1 (en) | 2016-06-08 |
AU2011276812A1 (en) | 2013-01-10 |
SG186931A1 (en) | 2013-02-28 |
KR101455055B1 (ko) | 2014-10-28 |
JP2013530190A (ja) | 2013-07-25 |
KR20130027547A (ko) | 2013-03-15 |
TW201217000A (en) | 2012-05-01 |
JP5685646B2 (ja) | 2015-03-18 |
TN2012000592A1 (en) | 2014-04-01 |
MY167896A (en) | 2018-09-26 |
CA2802443A1 (en) | 2012-01-12 |
CN102971011B (zh) | 2014-12-03 |
US20130149376A1 (en) | 2013-06-13 |
TWI457145B (zh) | 2014-10-21 |
AR081661A1 (es) | 2012-10-10 |
CA2802443C (en) | 2015-03-17 |
CO6640312A2 (es) | 2013-03-22 |
EA025333B1 (ru) | 2016-12-30 |
WO2012003814A1 (es) | 2012-01-12 |
EP2591802A1 (en) | 2013-05-15 |
ZA201300059B (en) | 2013-09-25 |
CN102971011A (zh) | 2013-03-13 |
EA201291449A1 (ru) | 2013-05-30 |
CL2012003674A1 (es) | 2013-07-12 |
PE20130390A1 (es) | 2013-04-11 |
BR112012033284A2 (pt) | 2017-05-02 |
HK1177138A1 (en) | 2013-08-16 |
ES2576851T3 (es) | 2016-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120413T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
EP4056198A3 (en) | Outer membrane vesicles | |
EA201291157A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
CO6781540A2 (es) | Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae | |
TR201802380T4 (tr) | Benzonaftiridin içeren aşılar. | |
EP2576578A4 (en) | POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF | |
EA201300585A1 (ru) | Иммуномодулирующие олигонуклеотиды | |
TR201908003T4 (tr) | TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları. | |
MX346094B (es) | Método de administración de vacunas. | |
UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
TR201903026T4 (tr) | S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari. | |
AR092372A1 (es) | Formulaciones de liposomas, uso y metodo de tratamiento | |
CO6640312A2 (es) | Composiciones vacunales a base de sticholisina encapsulada en liposomas | |
CL2012003458A1 (es) | Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico. | |
BR112015000585A2 (pt) | cepas mutantes de mycoplasma hyopneumoniae | |
BR112013028709A2 (pt) | cepas bacterianas capazes de metabolizar oxalatos | |
BR112015008417A8 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
EA201790558A1 (ru) | Композиция с пониженной иммуногенностью | |
IN2014CN03454A (es) | ||
EP2762153A3 (en) | Vaccine composition for mucosal administration | |
CY1118402T1 (el) | Η χρηση πηγης l3 και/ή l5 ως εμβολιου ή ως διαγνωστικου για παρασιτικη παθηση | |
NZ596501A (en) | Casb7439 constructs | |
BR112015013190A2 (pt) | preparação cosmética ou dermatológica à base de uma emulsão de água-em-óleo, uso de uma preparação, e uso de pelo menos 0,1 % em peso | |
CO6831981A2 (es) | Productos médicos para uso en enfermedades relacionadas con infecciones microbianas en el tracto aerodigestivo superior |